CPRD non-interventional population | TORCH trial population^{#} | |||

SAL | FP-SAL | SAL | FP-SAL | |

Subjects | 1146 | 11 235 | 1521 | 1533 |

Exacerbations | ||||

Person-years at risk | 2566 | 24 062 | ||

Events | 1515 | 14 034 | ||

Rate per person per year | 0.73 | 0.59 | 0.97 | 0.85 |

Crude rate ratio | 1 | 0.80 (0.72–0.88) | ||

Propensity matched rate ratio | 1 | 0.85 (0.74–0.97)^{+} | 1 | 0.88 (0.81–0.95) |

Mortality | ||||

Person-years at risk | 2566 | 24 062 | ||

Events | 138 | 1445 | ||

Probability at 3 years^{¶} % | 15.09 | 16.84 | 13.48 | 12.59 |

Crude hazard ratio | 1 | 1.12 (0.94–1.34) | ||

Propensity matched hazard ratio | 1 | 0.93 (0.65–1.32)^{§} | 1 | 0.93 (0.77–1.13) |

Pneumonia | ||||

Events | 86 | 1137 | ||

% of total patients | 7.50 | 10.12 | 13.29 | 19.60 |

Crude risk ratio | 1 | 1.35 (1.09–1.66) | ||

Propensity matched risk ratio | 1 | 1.39 (1.04–1.87)^{ƒ} | 1 | 1.47 (1.25–1.73) |

Time to treatment discontinuation | ||||

Person-years at risk | 1251 | 21 587 | ||

Events | 740 | 2449 | ||

Probability at 3 years^{¶} % | 77.02 | 28.04 | 36.40 | 33.70 |

Crude hazard ratio | 1 | 0.22 (0.20–0.23) | ||

Propensity matched hazard ratio | 1 | 0.23 (0.20–0.27)^{##} | 1 | 0.89 (0.79–0.99) |

Data are presented as n, unless otherwise stated. CPRD: Clinical Practice Research Datalink. ^{#}: only results reported in the TORCH trial publication are shown; ^{¶}: calculated using a Cox proportional-hazards model; ^{+}: n=991 in each exposure group after propensity score matching (see supplementary table A2-3 for list of variables contributing to propensity score for exacerbations analysis); ^{§}: n=443 in each exposure group after propensity score matching (see supplementary table A2-3 for list of variables contributing to propensity score for mortality analysis); ^{ƒ}: n=996 in each exposure group after propensity score matching. (see supplementary table A2-3 for list of variables contributing to propensity score for pneumonia analysis); ^{##}: n=935 in each exposure group after propensity score matching (see supplementary table A2-3 for list of variables contributing to propensity score for time to treatment discontinuation analysis).